VEGFA and neoplasm: Antiangiogenic therapy in the form of the anti-VEGF-A antibody bevacizumab has been tested in combination with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma demonstrating favorable clinical outcomes and was associated with improved tumor T cell infiltration (127, 128).